AAX Biotech to Attend Festival of Biologics 2026

AAX Biotech announced its participation in the Festival of Biologics in Basel, Switzerland, scheduled for October 13-15 at Messe Basel.

CEO and CSO Daniel X. Johansson is set to present a poster detailing the company's Opti-mAb® technology. This technology addresses scFv instability, a significant challenge in antibody therapeutics, aiming to reduce aggregation and enhance stability.

The Opti-mAb® platform is designed to improve the therapeutic performance of next-generation modalities, including bi- and multispecific antibodies, as well as CAR-T therapies. Johansson will be available at poster #1 to discuss the technology.

Additionally, AAX Biotech's partner, evitria AG, will present its evaluation results for Opti-mAb® at poster #56. AAX Biotech expressed enthusiasm for the collaboration and anticipates wider adoption of Opti-mAb® through evitria's services.

The company invites attendees interested in learning more to book a meeting with Johansson or engage in informal discussions during the event.